BLUE News and Press, bluebird bio Inc. From 05/30/22

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...

Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...

Switzerland's Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and bluebird bio (BLUE) are resolving a trademark infringement litigation related to the Cambridge, Mass.-based gene therapy company's sickle cell disease (SCD) awareness campaign, "Be the Spark," Fierce Pharma reported. Roche's gene t...

Bluebird bio (NASDAQ:BLUE) stock rose ~6% on May 17 amid Morgan Stanley lowering its price target on the gene therapy developer's shares to $3 from $5. Morgan Stanley analyst maintained an Underweight rating on the shares. Following the company's Q1 earnings about a week ago Barclay...

bluebird bio (BLUE +10.1%) Q1 shows a revenue beat of $1.78M to $1.95, up +119.1% Y/Y. Research and development expenses from continuing operations were $77.9 million for the three months ended March 31, 2022, compared to $82.8 million for the three months ended March 31, 2021. Restricted cas...

bluebird bio press release (NASDAQ:BLUE): Q1 GAAP EPS of -$1.66 misses by $0.30. Revenue of $1.95M (+119.1% Y/Y) beats by $1.78M. Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 For further details see: bluebird bio GAAP EPS of -$1...

- BLAs for beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-en...

Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million...